# Phase 1 endometrial cancer trials recruiting: 57 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials in phase 1 for endometrial cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 endometrial cancer trials: 57 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/endometrial-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 57
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| October 15, 2026 | NCT07874880 | MTX-531-001 Phase 1 Study in Advanced Solid Tumors | MEKanistic Therapeutics, Inc. | Phase 1 | Not yet recruiting | Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer, Pan-RAS and BRAF Wild-type... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874880) |
| October 13, 2026 | NCT07870278 | A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Ovarian Neoplasms, Endometrial Neoplasms | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870278) |
| September 11, 2026 | NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815951) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| August 10, 2026 | NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic... | ArriVent BioPharma, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755436) |
| July 20, 2026 | NCT07715747 | A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 1 | Recruiting | Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715747) |
| June 24, 2026 | NCT07664735 | A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | Outpace Bio, Inc. | Phase 1 | Recruiting | Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664735) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| April 13, 2026 | NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | Regor Pharmaceuticals Inc. | Phase 1 | Recruiting | Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation, HER2- Negative Breast Cancer, Advanced Breast... | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524322) |
| March 31, 2026 | NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503808) |
| March 13, 2026 | NCT07470853 | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Whitehawk Therapeutics, Inc. | Phase 1 | Recruiting | PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470853) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| March 3, 2026 | NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Whitehawk Therapeutics, Inc. | Phase 1 | Recruiting | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR... | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444814) |
| February 19, 2026 | NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Compass Therapeutics | Phase 1 | Recruiting | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419841) |
| February 3, 2026 | NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Cogent Biosciences, Inc. | Phase 1 | Recruiting | PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383506) |
| January 12, 2026 | NCT07334119 | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | Myeloid Therapeutics | Phase 1 | Recruiting | HER2-Expressing Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334119) |
| December 29, 2025 | NCT07306559 | A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours) | Boehringer Ingelheim | Phase 1 | Recruiting | Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced... | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07306559) |
| November 14, 2025 | NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | Kivu Bioscience Inc. | Phase 1 | Recruiting | Advance Solid Tumors | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229313) |
| November 12, 2025 | NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227168) |
| October 14, 2025 | NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Recruiting | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck... | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216105) |
| September 29, 2025 | NCT07197554 | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | SEED Therapeutics, Inc. | Phase 1 | Recruiting | Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC) | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197554) |
| September 19, 2025 | NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Normunity AccelCo, Inc. | Phase 1 | Recruiting | HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182149) |
| August 11, 2025 | NCT07114601 | A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Eli Lilly and Company | Phase 1 | Recruiting | Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach... | 421 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114601) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 4 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| Sutro Biopharma, Inc. | 2 |
| SystImmune Inc. | 2 |
| Whitehawk Therapeutics, Inc. | 2 |
| Cogent Biosciences, Inc. | 1 |
| Context Therapeutics Inc. | 1 |
| Kestrel Therapeutics, Inc. | 1 |
| SEED Therapeutics, Inc. | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| IDEAYA Biosciences | 1 |
| [Xencor, Inc.](https://specstream.ai/data/clinical-trials/company/xencor-inc) | 1 |
| TwoStep Therapeutics, Inc. | 1 |
| [TJ Biopharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/tj-biopharma-co-ltd) | 1 |
| Outpace Bio, Inc. | 1 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 1 |
| Danatlas Pharmaceuticals Co., Ltd | 1 |
| West China Hospital | 1 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 1 |
| Myeloid Therapeutics | 1 |
| Tongji Hospital | 1 |
| Sairopa B.V. | 1 |
| National Cancer Institute (NCI) | 1 |
| Pheast Therapeutics | 1 |
| TORL Biotherapeutics, LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 46 |
| Spain | 10 |
| China | 10 |
| France | 7 |
| Australia | 7 |
| United Kingdom | 6 |
| Japan | 6 |
| Belgium | 4 |
| South Korea | 3 |
| Germany | 3 |
| Italy | 3 |
| Canada | 2 |
| Georgia | 1 |
| Denmark | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Retina services clinics in the United States](https://specstream.ai/data/businesses/retina-services-clinics/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
